ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Awan Discusses Challenges With Ibrutinib in CLL

Farrukh Awan, MBBS
Published: Monday, Oct 16, 2017



Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

The key issues with usage of ibrutinib in patients with CLL are duration and the management of side effects.

Current ongoing trials are tackling these challenges, says Awan, results of which will hopefully bring more knowledge to the field.
 


Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

The key issues with usage of ibrutinib in patients with CLL are duration and the management of side effects.

Current ongoing trials are tackling these challenges, says Awan, results of which will hopefully bring more knowledge to the field.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x